California Physician Assistant Board Attorney Fee Petition Mechanics: Tyler Odyssey Civil Complaint Date as Primary Welch Anchor, PAB BreEZe License Verification Database as Secondary Institutional Anchor (the Only PAB BreEZe Module Anchor in This Series), CLRA § 1780 Mandatory Attorney Fees for Patients Harmed by Unlicensed Physician Assistant Practice Including Unlicensed Controlled Substance Prescribing Without DEA Certificate of Registration

Statutory Framework: Bus. & Prof. Code § 3526 and the Physician Assistant Practice Act — PAB License Requirements, Prohibited Conduct, and CLRA § 1780 Mandatory Attorney Fees for Unlicensed PA Practice

California Business and Professions Code § 3526 is the operative licensing prohibition of the Physician Assistant Practice Act, establishing that no person may engage in the practice of a physician assistant — which includes performing diagnostic workups, taking patient histories, performing physical examinations, ordering and interpreting laboratory tests and diagnostic imaging studies, formulating diagnoses, developing and implementing treatment plans, prescribing drugs and controlled substances, performing medical procedures under physician supervision, and providing patient counseling and education — without a valid license issued by the California Physician Assistant Board. Physician assistant practice in California is a supervised medical practice: the PA operates under a written Delegation of Services Agreement (DSA) with a supervising physician who is licensed by the Medical Board of California, and the DSA defines the specific procedures and prescribing authority delegated by the supervising physician to the PA within the supervising physician's scope of practice. Bus. & Prof. Code § 3502 authorizes licensed PAs to perform medical services as delegated by their supervising physicians; § 3502.1 authorizes licensed PAs to furnish drugs and devices, including Schedule II–V controlled substances, pursuant to a valid DSA and consistent with the PA's DEA Certificate of Registration.

The scope of § 3526 violations encompassing actionable CLRA § 1780 consumer fraud claims includes several distinct patterns of unlicensed PA practice: (1) individuals with healthcare education but without PAB licensure (including medical students, nursing students, pre-PA students, and foreign medical graduates without California medical or PA licensure) performing diagnostic evaluations, prescribing medications, and representing themselves as "physician assistants" or "PAs" to patients; (2) out-of-state licensed PAs from states with reciprocity agreements who perform PA services in California without a California PAB license — California does not automatically recognize PA licenses from other states, and PA practice in California for California patients requires a California PAB license issued after meeting California-specific requirements; (3) individuals whose PAB licenses have lapsed, been suspended, or been revoked who continue practicing as PAs or representing current PAB licensure in clinical settings; (4) medical assistants, medical scribes, or unlicensed clinical personnel who perform PA-scope functions under a physician's direction without holding PAB licensure and without a valid DSA; and (5) individuals operating telehealth platforms, weight loss clinics, pain management clinics, or direct-to-consumer healthcare services who provide PA-level medical services, including remote prescription of weight loss medications (GLP-1 receptor agonists, phentermine), controlled substances, or antibiotics, without valid California PAB licensure for each PA practitioner.

The CLRA civil remedy arises because physician assistant practice services — medical evaluation, diagnosis, treatment planning, prescription of medications and controlled substances, and patient counseling — are consumer services purchased by patients for their own personal and medical use, satisfying the definition of "consumer services" under Civil Code § 1761(b). Every PA practice that represents to the public that its practitioners hold current PAB licenses — in patient intake forms, clinic websites, electronic health record system provider identifiers, NPI (National Provider Identifier) representations, and DEA registration representations — when practitioners lack current PAB licensure constitutes a misrepresentation of service provider qualifications under Civil Code § 1770(a)(14). Section 1780(e) mandates that "the court shall award court costs and attorney's fees to a prevailing plaintiff in litigation filed pursuant to this section" — eliminating judicial discretion entirely.

Three Unique Distinctions in the Fee-Petition-Mechanics Series

• THE ONLY PAB BreEZe Module anchor in the entire fee-petition-mechanics series — the PAB administers a separate BreEZe module that licenses California physician assistants under the Physician Assistant Practice Act, a licensing program entirely distinct from all other DCA healing arts BreEZe modules: the California Physician Assistant Board maintains its own BreEZe module that is the only secondary anchor in the series tied to the PAB's PA licensing program; the PAB BreEZe module is categorically distinct from: the MBC BreEZe module, which covers licensed physicians and surgeons (MD and DO licensees under the Medical Practice Act, Bus. & Prof. Code §§ 2000–2429), osteopathic physicians, and podiatric physicians — practitioners who practice medicine independently without the DSA supervision requirement applicable to PAs; the BRN BreEZe module, which covers registered nurses (RNs) licensed under the Nursing Practice Act (Bus. & Prof. Code §§ 2700–2838) — nurses who provide nursing care within the scope of the Nursing Practice Act but are not authorized to independently perform the diagnostic and prescribing functions that a licensed PA performs under physician delegation; the BOP BreEZe module, which covers licensed psychologists (PsyD, PhD) who provide mental health diagnosis and treatment under the Psychology Licensing Law — professionals who do not prescribe medications and operate in a distinct clinical scope from PAs; the BVNPT BreEZe module, which covers LVNs and psychiatric technicians under separate non-PA licensing programs; and the RCB, CBOT, PTB, SLPAHADB, and all other DCA healing arts board BreEZe modules in the series; a person holding a current BRN registered nurse license, an MBC medical assistant certification, or any other DCA healing arts credential is not thereby authorized to practice as a physician assistant, use the title "PA" or "PA-C," or prescribe medications or controlled substances under a DSA without a valid PAB license under § 3526; the PAB BreEZe module is THE ONLY PAB BreEZe module anchor in the fee-petition-mechanics series.
• THE ONLY page where unlicensed practice involves SCHEDULE II–V CONTROLLED SUBSTANCE PRESCRIBING requiring a DEA Certificate of Registration (COR) as a predicate — every controlled substance prescription issued by an unlicensed PA lacks the DEA COR authority required for lawful prescribing and constitutes a federal controlled substance violation: California-licensed PAs who are authorized by their supervising physician's DSA to prescribe controlled substances (Schedule II–V) under Bus. & Prof. Code § 3502.1 must hold their own DEA Certificate of Registration in the PA license classification (DEA registrant type "M" for mid-level practitioners, specifically the PA subtype); the DEA COR for a PA requires as a predicate the PA's valid state professional license — here, the California PAB license; when a person practices as a PA without PAB licensure: (a) they cannot lawfully hold a DEA COR in the PA license type, because the DEA application for a mid-level practitioner COR requires a valid state license number and confirmation of state licensure authority to prescribe controlled substances; (b) any controlled substance prescriptions they issue — including Schedule II opioids (oxycodone, hydrocodone, fentanyl, morphine), Schedule II stimulants (amphetamine mixed salts, methylphenidate), Schedule III–IV opioids (buprenorphine, tramadol), Schedule IV benzodiazepines (alprazolam, lorazepam, clonazepam, diazepam), and Schedule IV sleep aids (zolpidem, eszopiclone) — are issued without lawful DEA registration authority, constituting federal controlled substance distribution violations under 21 U.S.C. § 841(a)(1) (distribution of controlled substances without DEA registration); (c) pharmacies that fill such prescriptions without verifying the prescriber's DEA COR and PAB licensure face DEA enforcement for dispensing controlled substances on unauthorized prescriptions; and (d) patients who receive controlled substance prescriptions from unlicensed PAs have received medications prescribed in violation of both California law (§ 3526) and federal DEA regulations (21 C.F.R. § 1306.03) — creating a CLRA § 1770(a)(14) misrepresentation claim that encompasses both the credential misrepresentation and the unlawful nature of the controlled substance prescription itself.
• THE ONLY page where victim class includes PATIENTS WHO RECEIVED OPIOID, STIMULANT, OR BENZODIAZEPINE PRESCRIPTIONS from unlicensed PAs who lacked both PAB licensure and valid DEA COR authority — patients harmed by the prescriber's lack of PAB-mandated training in CURES 2.0 protocols, controlled substance monitoring, and mandatory prescriber-patient agreements: the California Controlled Substances Utilization Review and Evaluation System (CURES 2.0), administered by the California Department of Justice, requires California-licensed prescribers (including licensed PAs) to query CURES before prescribing Schedule II–IV controlled substances for the first time to a new patient and to query CURES at specified intervals thereafter; CURES 2.0 queries reveal: the patient's prior controlled substance prescription history from all California prescribers, which allows the prescriber to identify patients receiving controlled substances from multiple prescribers (a pattern associated with opioid misuse and diversion), to assess the appropriateness of the current prescription request against the patient's documented treatment history, and to comply with California's mandatory prescriber-patient controlled substance agreements for chronic pain patients receiving Schedule II opioids; unlicensed PAs lack PAB-mandated training in CURES 2.0 query protocols and the clinical judgment framework required by the PAB's continuing education requirements for controlled substance prescribers; patients who received Schedule II opioid prescriptions from unlicensed PAs without proper CURES 2.0 query and without mandatory prescriber-patient opioid agreements may have received opioid prescriptions at doses, durations, or in combinations (opioid plus benzodiazepine) that violate California prescribing guidelines established by the Medical Board of California and the PAB — exposing patients to opioid misuse risk, physical dependence, and overdose harm directly attributable to the unlicensed practitioner's failure to apply PAB-required controlled substance monitoring protocols.

PURE KETCHUM — Bus. & Prof. Code § 3526 unlicensed PA practice claims with no concurrent federal statute providing mandatory consumer attorney fee-shifting; no Ketchum/Dague split for the CLRA § 1780 lodestar: no federal statute creates a private consumer right of action with mandatory attorney fees against unlicensed physician assistants; the False Claims Act (31 U.S.C. § 3730) provides qui tam relator standing for fraud against government healthcare programs but creates no mandatory consumer fee-shifting claim available to the individual patient harmed by unlicensed PA credential misrepresentation; the Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a) is an administrative enforcement mechanism available to the Department of Health and Human Services Office of Inspector General — not a private consumer cause of action; for the CLRA § 1780 unlicensed PA practice claim, the entire lodestar from the PAB BreEZe search date through the Tyler Odyssey complaint through judgment is pure Ketchum, eligible for the full Ketchum v. Moses contingency multiplier without any Dague constraint.

Primary Welch Anchor: Tyler Odyssey Civil Complaint Filing Date

The Tyler Odyssey civil complaint filing date is the primary Welch temporal anchor for the CLRA § 1780 attorney fee petition lodestar in Bus. & Prof. Code § 3526 unlicensed PA practice cases. In unlicensed PA matters, the Tyler Odyssey complaint is typically filed after the plaintiff attorney has: confirmed through the PAB BreEZe module that the defendant lacks a current active PAB license; reviewed the patient's medical records, intake forms, prescription records, and any controlled substance prescriptions issued by the defendant to document the specific PA services performed under the unlicensed credential; investigated the defendant's DEA registration status through the DEA Diversion Control Division's online registrant search to confirm the absence or invalidity of a DEA COR for the unlicensed PA practice; and assessed the full scope of the patient's harm — the clinical harm from receiving services from an unlicensed practitioner and, in controlled substance cases, the harm from receiving opioid, stimulant, or benzodiazepine prescriptions without PAB-mandated controlled substance monitoring protocols.

The pre-complaint advisory period in unlicensed PA practice cases can be initiated through several discovery pathways: a patient who discovers after receiving medical treatment that the person they believed was a licensed PA was practicing without PAB licensure; a patient who received controlled substance prescriptions from a practitioner representing PA status and discovers that the prescriptions were issued without valid DEA COR authority; a patient who suffered a medication error, drug interaction harm, or opioid dependence injury traceable to an unlicensed PA's prescribing decisions that violated CURES 2.0 protocols and PAB controlled substance prescribing standards; a patient who engaged a weight loss clinic, telehealth platform, or direct-to-consumer health service and discovers that the practitioners prescribing GLP-1 medications, stimulants, or controlled appetite suppressants were practicing without valid California PAB licensure; or a patient's family member who discovers post-treatment that the treating clinician was not PAB-licensed after reviewing the provider's licensure status in connection with a malpractice investigation.

Secondary Institutional Anchor: PAB BreEZe License Verification Database

The California Physician Assistant Board BreEZe License Verification Database is the secondary institutional anchor in CLRA § 1780 unlicensed PA practice fee petition cases — THE ONLY secondary institutional anchor in the entire fee-petition-mechanics series tied specifically to the PAB's PA licensing program under Bus. & Prof. Code §§ 3500–3546. The PAB maintains its BreEZe module with records for each California-licensed PA: the PA's full legal name; the PAB license number (PA-xxxxx series issued by the PAB registration system); the license issue date; the license expiration date (biennial renewal); the current license status (Active, Inactive, Suspended, Revoked, Surrendered, or Delinquent); any disciplinary conditions or probationary restrictions imposed by the PAB following formal disciplinary proceedings; any public enforcement actions, including formal accusations, consent agreements, and license revocations; and the PA's business address of record. The PAB BreEZe module is maintained entirely separately from the MBC BreEZe module (which covers physicians and surgeons, osteopathic physicians), the BRN BreEZe module (registered nurses), and all other DCA healing arts board BreEZe modules.

When the attorney searches the PAB BreEZe module and confirms the defendant's absence from the active PA licensee roster — or confirms that the defendant holds a lapsed, expired, suspended, or revoked PAB license — the search date establishes the secondary Welch anchor. In controlled substance cases, the attorney cross-references the DEA Diversion Control Division registrant database to confirm the absence of a valid DEA COR in the PA license type associated with the defendant's claimed PAB license number — establishing that the defendant's controlled substance prescribing lacked both the state license predicate (PAB licensure under § 3526) and the federal registration predicate (DEA COR under 21 U.S.C. § 823(f)). The PAB BreEZe search result — a screenshot or printout confirming the defendant's unlicensed PA status as of the search date — is preserved as an exhibit to the CLRA § 1780 fee petition, establishing the secondary anchor date from which all attorney time in the lodestar flows.

Billing Gap 1 — PAB BreEZe Database Search, DEA Registrant Database Cross-Reference, and Medical Records Review (4.50 hrs/yr = $1,350–$2,250)

The first billing gap arises in the pre-complaint advisory phase — from initial patient contact through Tyler Odyssey complaint filing — during which the attorney searches the PAB BreEZe module to confirm unlicensed PA status, cross-references the DEA Diversion Control Division registrant database to confirm the absence of a valid DEA COR for any controlled substance prescriptions issued, reviews the patient's medical records to document the scope of unlicensed PA services received, and evaluates the controlled substance prescription records to identify any Schedule II–V prescriptions issued without DEA COR authority.

• Searching the PAB BreEZe module and cross-referencing the DEA registrant database to confirm the defendant's complete absence of California PA licensure and DEA COR authority for any controlled substance prescriptions issued: the attorney searches the PAB BreEZe module for the defendant practitioner to confirm: (a) the absence of a current active PAB license in the PA-xxxxx series; (b) whether the defendant holds any inactive, lapsed, suspended, or revoked PAB license; (c) whether the defendant was ever PAB-licensed; the attorney also cross-references the DEA Diversion Control Division's online registrant verification tool at deadiversion.usdoj.gov to confirm whether the defendant holds or ever held a DEA COR in the PA mid-level practitioner classification ("M" type) — establishing that any controlled substance prescriptions issued by the unlicensed PA lacked both state PAB licensure authority and federal DEA registration authority; the attorney further reviews the defendant's clinical credential representations in patient intake forms, clinic website provider directories, electronic health record system provider identifiers, and NPI registry entries to document the specific misrepresentations of PAB licensure that induced the patient to receive medical services from the unlicensed practitioner.
• Reviewing the patient's complete medical records — including intake forms, clinical visit notes, order sets, prescription records, and pharmacy fill history — to document the specific PA-scope services performed by the unlicensed practitioner and to identify all controlled substance prescriptions issued without DEA COR authority: the attorney reviews all clinical records generated by the unlicensed PA including: the patient intake form (confirming the practitioner's self-identification as a "physician assistant," "PA," or "PA-C" and the PAB license number represented); the clinical visit notes authored by the unlicensed PA (documenting the diagnostic assessments, treatment plans, and prescribing decisions made by the unlicensed practitioner under the guise of PA licensure); the medication order records (identifying each prescription issued by the unlicensed PA, including the Schedule classification for any controlled substance prescriptions); the pharmacy fill history (confirming which prescriptions were filled by pharmacies that did not verify the prescriber's PAB licensure and DEA COR status before dispensing); and the CURES 2.0 patient activity report (available to the patient or their attorney through a CURES patient request) documenting the controlled substance prescription history associated with the unlicensed practitioner as the issuing prescriber.
• Assessing the specific clinical harm to the patient from receiving diagnostic, treatment, and prescribing services from an unlicensed PA who lacked PAB-mandated training in differential diagnosis, evidence-based prescribing, and controlled substance monitoring protocols: the attorney evaluates the clinical harm suffered by the patient as a result of receiving healthcare services from an unlicensed PA, including: (a) diagnostic errors or missed diagnoses attributable to the unlicensed practitioner's lack of ARC-PA-accredited PA program training in systematic clinical evaluation, differential diagnosis methodology, and evidence-based treatment selection; (b) prescribing errors, drug interaction harms, or contraindicated medication selection attributable to the unlicensed practitioner's lack of PAB-required pharmacology training; (c) controlled substance dependency, withdrawal harm, or overdose risk attributable to the unlicensed practitioner's failure to apply CURES 2.0 prescriber query protocols, mandatory prescriber-patient opioid agreements, and CDC opioid prescribing guideline thresholds that PAB-licensed PAs are required to follow; and (d) continuity-of-care disruption when the patient discovers the unlicensed status and must transition care to a licensed provider who must evaluate and potentially modify the treatment plan established by the unlicensed practitioner.

Billing Gap 2 — Clinical Expert Depositions, DEA Enforcement Records, and Controlled Substance Prescribing Pattern Analysis (5.00 hrs/yr = $1,500–$2,500)

The second billing gap arises from the active litigation phase — from Tyler Odyssey complaint through trial or settlement — during which the attorney prepares and takes or defends depositions of licensed PA or physician standard-of-care experts on the PA practice standard-of-care violations, obtains and reviews DEA enforcement records relating to any unlicensed controlled substance prescribing by the defendant, and develops documentary evidence of the controlled substance prescribing pattern harm — including CURES 2.0 patient activity reports, pharmacy dispensing records, and clinical harm documentation that connects the unlicensed PA's prescribing decisions to the patient's injury.

• Preparing and taking depositions of licensed PA or physician standard-of-care experts on the PAB licensure requirements, the specific PA clinical practice standard-of-care violations, and the clinical harm caused by the absence of ARC-PA-accredited PA program training and PAB continuing education requirements in the unlicensed practitioner's practice: the attorney prepares for and takes or defends deposition of the retained standard-of-care expert — a California-licensed PA (PA-C) or supervising physician with experience in PA clinical practice evaluation — on: (a) the California PAB licensure requirements: the ARC-PA-accredited master's-level PA program requirement, the PANCE examination through NCCPA, the DSA supervising physician requirement, and the PAB biennial CE requirements including mandatory controlled substance prescribing and pain management CE topics; (b) the specific PA practice standard-of-care violations caused by the unlicensed practitioner's training gaps in differential diagnosis, evidence-based treatment selection, controlled substance prescribing, and CURES 2.0 compliance; (c) the DEA COR requirement for controlled substance prescribing by PAs and the federal controlled substance law violations arising from controlled substance prescriptions issued by a practitioner lacking both PAB licensure (the state predicate) and DEA COR (the federal predicate); and (d) the specific clinical harm to the patient from the unlicensed prescribing decisions — the missed CURES 2.0 queries, contraindicated drug combinations, inappropriate opioid dosage escalation, or failure to implement mandatory prescriber-patient agreements for long-term controlled substance therapy.
• Obtaining and reviewing DEA enforcement records, pharmacy dispensing records, and CURES 2.0 patient activity reports to document the full scope of the unlicensed controlled substance prescribing pattern and its effect on the patient's health and recovery trajectory: the attorney conducts discovery targeting the unlicensed controlled substance prescribing evidence including: DEA Diversion Control Division enforcement records (if any) relating to the defendant's controlled substance prescribing activity without valid DEA COR, available through FOIA requests or subpoena of DEA district office files; pharmacy dispensing records showing each controlled substance prescription filled for the patient issued by the unlicensed practitioner — documenting the Schedule classification, dosage, days' supply, and dispensing pharmacist's validation of the prescriber's DEA COR number; the patient's CURES 2.0 activity report obtained through patient authorization (Health & Safety Code § 11165.6 authorizes patients to request their own CURES records) documenting all controlled substance prescriptions in the patient's history, allowing comparison between the unlicensed PA's prescribing pattern and the prior prescribing history to quantify the escalation of controlled substance use attributable to the unlicensed prescriber; and treating physician records from the licensed provider who assumed the patient's care after the unlicensed PA was identified — documenting the clinical transition steps required to safely discontinue or modify the controlled substance regimen initiated by the unlicensed practitioner, including controlled substance taper protocols for opioid-dependent patients.
• Developing the specific CLRA § 1770(a)(14) misrepresentation theory encompassing both the PAB credential misrepresentation and the unlawful nature of the controlled substance prescriptions — establishing the dual federal-state violation as a multiplier factor for the CLRA § 1780 fee petition: the attorney develops the CLRA § 1780 misrepresentation theory in full, documenting: (a) the specific representations made by the unlicensed practitioner to the patient regarding PAB licensure status — the use of "PA" or "PA-C" title designations on clinical intake forms, the representation of a PAB license number in electronic health records or prescription pad headers, and the billing of services under an NPI that the unlicensed practitioner was not lawfully entitled to use; (b) the patient's reasonable reliance on those representations in engaging the medical services and accepting the prescription treatment plan; (c) the dual federal-state violation in controlled substance cases — the simultaneous § 3526 state licensing violation and the 21 U.S.C. § 841(a)(1) federal controlled substance distribution violation arising from prescribing without DEA COR authority; and (d) the connection between the dual violation and the patient's actual harm — the clinical injuries, medication harm, or controlled substance dependency directly traceable to the unlicensed practitioner's credential misrepresentation and the consequent delivery of services without PAB-mandated training in safe prescribing practice.

Billing Gap 3 — CLRA § 1780 Fee Petition: Lodestar Compilation, Ketchum v. Moses Multiplier Briefing, and PLCM Group Hourly Rate Affidavits (4.00 hrs/yr = $1,200–$2,000)

The third billing gap arises from the CLRA § 1780 mandatory attorney fee petition — establishing the complete lodestar from the PAB BreEZe search date (secondary anchor) through the Tyler Odyssey complaint (primary Welch anchor) and judgment, briefing the Ketchum multiplier with emphasis on the controlled substance prescribing complexity unique to unlicensed PA practice litigation, and recovering fees-on-fees under Missouri v. Jenkins for all fee petition preparation time.

• Documenting the complete CLRA § 1780 lodestar from the PAB BreEZe Database search date (secondary anchor) through the Tyler Odyssey complaint (primary Welch anchor) and judgment — including the PAB database search session, DEA registrant cross-reference, medical records review, controlled substance harm assessment, clinical standard-of-care expert consultation, Tyler Odyssey complaint filing, and judgment or settlement: the CLRA § 1780 fee petition documents the complete lodestar beginning with the PAB BreEZe module search session that established the secondary anchor and confirmed the defendant's absence from the PAB active licensee roster; the narrative explains that the PAB BreEZe module is the only secondary anchor in the fee-petition-mechanics series tied to the Physician Assistant Practice Act — entirely distinct from the MBC BreEZe (physicians), BRN BreEZe (RNs), BOP BreEZe (psychologists), BVNPT BreEZe (LVNs), and all other DCA healing arts board BreEZe modules in the series; the narrative applies the Hensley v. Eckerhart (461 U.S. 424 (1983)) lodestar reasonableness framework to document the relationship between the pre-complaint advisory tasks (PAB database search, DEA registrant cross-reference, medical records review, CURES 2.0 patient activity report, clinical standard-of-care expert consultation) and the active litigation tasks (clinical expert deposition, DEA enforcement records discovery, controlled substance prescribing pattern analysis) and the overall successful result in the CLRA § 1780 claim.
• Ketchum multiplier factors specific to CLRA § 1780 unlicensed PA practice cases involving controlled substance prescribing without DEA COR authority — emphasizing the dual federal-state violation complexity, the DEA and CURES 2.0 regulatory expertise burden, and the PURE KETCHUM status with no Dague constraint on any portion of the fee award: the Ketchum v. Moses (24 Cal.4th 1122 (2001)) contingency multiplier analysis for unlicensed PA practice cases involving controlled substance prescribing without DEA COR has several strong multiplier dimensions: (a) the dual federal-state regulatory complexity premium — unlicensed PA practice cases with controlled substance prescribing require expertise in both the California PAB licensing framework (the Physician Assistant Practice Act, DSA requirements, CURES 2.0 prescribing obligations) and the federal controlled substance regulatory framework (DEA COR requirements under 21 U.S.C. § 823(f), Schedule II–V prescribing authority, and the federal distribution violation under 21 U.S.C. § 841(a)(1)) — a dual-regulatory-expertise burden that commands a premium above the standard consumer protection practice rate; (b) the PURE KETCHUM status — no federal statute creates a parallel mandatory consumer fee-shifting mechanism for individual patients harmed by unlicensed PA credential misrepresentation and unauthorized controlled substance prescribing; (c) the controlled substance harm complexity — cases involving opioid dependency, benzodiazepine withdrawal injury, or stimulant misuse harm require collaboration with addiction medicine experts, pharmacological harm experts, and CURES 2.0 prescribing audit specialists — a clinical expert coordination burden unique to the PAB unlicensed practice page; and (d) the DEA enforcement and pharmacy regulatory dimension — tracing the controlled substance prescribing chain through DEA registrant records, pharmacy dispensing records, and CURES 2.0 patient activity reports requires regulatory investigation expertise available only to attorneys with combined healthcare regulatory and consumer protection plaintiff bar experience.
• PLCM Group Inc. v. Drexler (22 Cal.4th 1084 (2000)) market rate affidavits for the PAB-specific PA practice litigation expertise premium — including market rate evidence for dual federal-state controlled substance regulatory litigation and Missouri v. Jenkins (491 U.S. 274 (1989)) fees-on-fees recovery for all fee petition preparation time: the PLCM Group market rate analysis documents the prevailing hourly rate for a solo practitioner handling CLRA § 1780 unlicensed PA practice cases involving controlled substance prescribing without DEA COR — a rate reflecting the specialized premium for: California PAB licensing framework expertise (Physician Assistant Practice Act, DSA requirements, PAB BreEZe module proficiency); federal controlled substance regulatory expertise (DEA COR requirements, 21 U.S.C. § 823(f) and § 841(a)(1), Schedule II–V prescribing authority analysis); CURES 2.0 prescribing audit methodology; clinical standard-of-care analysis for PA practice with opioid, stimulant, and benzodiazepine prescribing; and the full PAB BreEZe module search, DEA registrant cross-reference, medical records review, and controlled substance harm documentation unique to the PAB unlicensed practice page; Missouri v. Jenkins (491 U.S. 274 (1989)) fees-on-fees recovery encompasses all time preparing the CLRA § 1780 fee petition including the PAB database search narrative, secondary anchor establishment, dual federal-state violation summary, Ketchum multiplier briefing, and PLCM Group market rate affidavit.

Total Annual Billing Gap — Three-Gap Summary

• Gap 1 (PAB BreEZe search, DEA registrant cross-reference, medical records review): 4.50 hrs = $1,350–$2,250/yr
• Gap 2 (clinical expert depositions, DEA enforcement records, CURES 2.0 prescribing pattern analysis): 5.00 hrs = $1,500–$2,500/yr
• Gap 3 (CLRA § 1780 fee petition, Ketchum v. Moses multiplier briefing & PLCM Group hourly rate affidavits): 4.00 hrs = $1,200–$2,000/yr
• Total: 13.50 hrs = $4,050–$6,750/yr untracked at $300–$500/hr median California solo practitioner rate

Related California Attorney Fee Petition Pages

• California Board of Registered Nursing — Bus. & Prof. Code § 2878
• California Medical Board — Bus. & Prof. Code § 2052
• California Board of Pharmacy — Bus. & Prof. Code § 4324
• California Board of Vocational Nursing and Psychiatric Technicians — Bus. & Prof. Code § 2864
• California Board of Psychology — Bus. & Prof. Code § 2914
• California Board of Behavioral Sciences — Civil Code § 43.93